



Q3 2019 Update

# DISCLAIMER

This presentation includes forward-looking statements about Axiomm Technologies Ltd. and its business. Often, but not always, forward-looking statements can be identified by the use of words such as “plan”, “continue”, “expect”, “schedule”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “propose” and other similar words or statements (including negative variations) that certain events or conditions may or will occur.

These forward-looking statements include, but are not limited to, statements regarding benefits and timing of the receipt of licensed processor status by Health Canada, the effects of Axiomm’s technology as applied to products containing cannabinoids, the success of research and development efforts, and the legalization of edible and certain other cannabis products in Canada. There are a number of risks and uncertainties associated that could cause actual results to differ materially from the forward-looking statements included in this presentation. For example, the expected timing and likelihood of the receipt of a standard processing license and the achievement of timely revenue by Axiomm. Such factors can be difficult to predict and may be beyond Axiomm’s control.

Furthermore, the forward-looking events and circumstances discussed in this presentation may not occur by certain specified dates or at all, and could differ materially as a result of unknown and known risk factors and uncertainties affecting Axiomm. Accordingly, Axiomm cautions that this foregoing list of material factors is not exhaustive.

The forward-looking information contained in this presentation represents expectations of Axiomm as of the date of this presentation and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While Axiomm may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable securities laws.

## Q3 2019 UPDATE

Q3 of 2019 saw Axiomm reach significant milestones in the commercialization of its technology:

1. **Announced a partnership with Qsonica** – leaders in the design, development and manufacturing of ultrasonic liquid processors for over 40 years, producing some of the most powerful, technologically advanced and reliable ultrasonic devices on the market – to provide the international market with turnkey, plug-and-play infusion technology solutions.
2. **Announced Axiomm’s turnkey solution:  $\mu$ GOO**, a precursor technology that allows anyone to infuse their liquid-based products (beverages, gummies, tinctures) with oils of all types: including hemp-derived CBD, vitamin and flavor oils. Our technology completely eliminates the need for Axiomm’s customers to engage in costly, time-consuming R&D that carries no guarantee of success. See [www.axiomm.com/goo](http://www.axiomm.com/goo) for more information.
3. **Achieved first revenue** from sales of our technology precursor,  $\mu$ GOO.
4. **Received a strategic investment from Southern Sky Group**, a leading retailer of CBD products in South Africa. The partnership presents an exciting opportunity to deploy our technology with a partner who has an established brand and distribution in South Africa.
5. **Received a strategic investment from iCAN**, an Israel-based organization providing scientific services and with business interests in Israel.
6. **Acquired a 50% interest in a Tennessee-based joint venture**. The joint venture will manufacture and supply Axiomm’s  $\mu$ SHOT to businesses in the state of Tennessee who are operating in the federally legal hemp-derived CBD industry.
7. **Submitted an application for its facility building permit**, putting Axiomm on track to receive its standard processing license in Q2 of 2020.





[www.axiommm.com](http://www.axiommm.com)

Questions? Please contact us at

[andrew@axiommm.com](mailto:andrew@axiommm.com)